Group items tagged

Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C Int J Cancer. 2008 Sep 15;123(6):1227-39. Review. PMID: 18623084

Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA. Zyflamend((R))-Mediated Inhibition of Human Prostate Cancer PC3 Cell Proliferation: Effects on 12-LOX and Rb Protein Phosphorylation. Cancer Biol Ther. 2007 Feb 25;6(2) [Epub ahead of pr

Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther. 2004 Sep;3(9):847-52. Epub 2004 Sep 18. P

Anticancer properties of oxidation products of docosahexaenoic acid. Siddiqui RA, Harvey K, Stillwell W. Chem Phys Lipids. 2008 May;153(1):47-56. Epub 2008 Feb 23. Review. PMID: 18343223

Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. Frank MB, Yang Q, Osban J, Azzarello JT, Saban MR, Saban R, Ashley RA, Welter JC, Fung KM, Lin HK. BMC Complement Altern Med. 2009 Mar 18;9(1):6. [Epub ahead of print] PMID: 19296830 doi:10.1186/1472-6882-9-6

Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ, Eibl G. Pancreas. 2008 May;36(4):353-62. PMID: 18437081 doi: 10.1097/MPA.0b013e31815ccc44

The application of probiotics in cancer. de Moreno de LeBlanc A, Matar C, Perdigón G. Br J Nutr. 2007 Oct;98 Suppl 1:S105-10. Review. PMID: 17922945 doi:10.1017/S0007114507839602

Our findings suggest that administration of n-3 FA (EPA and DHA) in doses of at least 1.5 g/day for a prolonged period of time to patients with advanced cancer is associated with an improvement in clinical, biological and QoL parameters. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C. Br J Nutr. 2007 May;97(5):823-31. Review. PMID: 17408522 doi:10.1017/S000711450765795X

Not enough vitamin D: health consequences for Canadians. Schwalfenberg G. Can Fam Physician. 2007 May;53(5):841-54. Review PMID: 17872747 Conclusion Low levels of VTD are considered a major public health problem in Canada, especially during the winter. Those with risk factors should be screened for low 25(OH)D levels and repletion therapy instituted if needed. Researchers have estimated that the oral dose of vitamin D3 to attain and maintain 25(OH)D levels >80 nmol/L is 2200 IU/d if baseline levels are 20 to 40 nmol/L, 1800 IU/d if levels are 40 to 60 nmol/L, and 1160 IU/d if levels are between 60 and 80 nmol/L.64 We need to ensure that patients have healthy blood levels of 25(OH)D to prevent levels of parathyroid hormone from rising and to maximize absorption of calcium, magnesium, and phosphate. Positive effects on bone are marginal at best unless patients consume at least 800 IU/d of VTD. The emerging and exciting role of the VTD receptor and the actions of VTD in maintaining health in other cell types have become more apparent during the last decade.